For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 62,065 | |||
| General and administrative | 10,282 | |||
| Total operating expenses | 72,347 | |||
| Loss from operations | -72,347 | |||
| Interest income | 1,562 | |||
| Other income | 790 | |||
| Interest expense | 0 | |||
| Total other income, net | 2,352 | |||
| Loss before income taxes | -69,995 | |||
| Federal tax at statutory rate | 14,699 | |||
| Permanent differences | -219 | |||
| Research and development credits | -2,485 | |||
| Change in valuation allowance | -16,965 | |||
| Income tax benefit | 0 | |||
| Net loss | -69,995 | |||
| Net unrealized gains on marketable securities | 60 | |||
| Total other comprehensive income | 60 | |||
| Total comprehensive loss | -69,935 | |||
| Basic EPS | -111.91 | |||
| Diluted EPS | -111.91 | |||
| Basic Average Shares | 744,991 | |||
| Diluted Average Shares | 744,991 | |||
Veradermics, Inc (MANE)
Veradermics, Inc (MANE)